Serum chelatable redox-active iron is an independent predictor of mortality after myocardial infarction in individuals with diabetes

Diabetes Care

Volumn 27, Issue 11, 2004, Pages 2730-2732

  Sulieman, Mahmoud ^a   Asleh, Rabea ^b   Cabantchik, Zvi I ^c   Breuer, William ^c   Aronson, Doron ^a   Suleiman, Abeer ^b   Miller Lotan, Rachel ^b   Hammerman, Haim ^a   Levy, Andrew P ^b  

^a RAMBAM MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CITRIC ACID; IRON; REACTIVE OXYGEN METABOLITE; SERUM ALBUMIN;

ACUTE HEART INFARCTION; AGE; ANGIOPLASTY; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; CONTROLLED STUDY; DIABETES MELLITUS; FIBRINOLYTIC THERAPY; HEART RATE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IRON BLOOD LEVEL; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MORTALITY; OXIDATIVE STRESS; SEX; SMOKING; ST SEGMENT ELEVATION; STATISTICAL ANALYSIS;

CASE-CONTROL STUDIES; DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; IRON; MYOCARDIAL INFARCTION; OXIDATION-REDUCTION; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES;

EID: 7444247268     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.27.11.2730     Document Type: Article

References (15)

1. Halliwell B, Gutteridge JM: Role of free radicals and catalytic metal ions in human disease: an overview. Meth Enz 186:1-85, 1990
2. Sullivan JL: Iron and sex differences in heart disease risk (Letter). Lancet 1:1293-1294, 1981
3. Danesh J, Appleby P: Coronary heart disease and iron status: meta-analysis of prospective studies. Circulation 99:852-854, 1999
4. Shah SV, Alam MG: Role of iron in atherosclerosis. Am J Kid Dis 41 (Suppl. 1): 80-83, 2003
5. Breuer W, Hershko C, Cabantchik ZI: The importance of non-transferrin iron in disorders of iron metabolism. Transfusion Sci 23:185-192, 2000
6. Breuer W, Cabantchik ZI: A fluorescence-based one step assay for serum non-transferrin bound iron (NTBI). Anal Biochem 299:194-202, 2001
7. Baykan M, Celik U, Orem A, Malkoc M, Erdol C, Baykan EC, Orem C, Karahan B: Iron status and its relationship with lipid peroxidation in patients with acute myocardial infarction. Acta Cardiol 56:277-281, 2001
8. Griffiths JD, Campbell LJ, Woodruff IW, Cruickshank D, Matthews JP, Hunt D, Campbell DG, Cowling DC: Acute changes in iron metabolism following myocardial infarction. Am J Clin Path 84:649-654, 1985
9. Esposito BP, Breuer W, Sirankapracha P, Pootrakul P, Hersko C, Cabantchik ZI: Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood 102:2670-2677, 2003
10. Esposito BP, Breuer W, Slotki I, Cabantchik ZI: Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin-bound iron in dialysis patients. Eur J Clin Invest 32 (Suppl. 1):42-49, 2002
11. Qian M, Liu M, Eaton JW: Transition metals bind to glycated proteins forming redox active "glycochelates": implications for the pathogenesis of certain diabetic complications. Biochem Biophys Res Comm 250:385-389, 1998.
12. Panter SS: Release of iron from hemoglobin. Meth Enz 231:502-514, 1994
13. Gutteridge JM: Iron promoters of the Fenton reaction and lipid peroxidation can be released from hemoglobin by peroxides. FEBS Lett 201:291-295, 1986
14. Puppo A, Halliwell B: Formation of hydroxyl radicals from hydrogen peroxides in the presences of iron: is hemoglobin a biological fenton reagent? Biochem J 249:185-190, 1988
15. Fujimoto S, Kawakami N, Ohara N: Non-enzymatic glycation of transferrin: decrease of iron-binding capacity and increase in oxygen radical production. Bio Pharm Bull 18:396-400, 1995